Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a
dietary phosphate binder in controlling and managing serum phosphorus levels in patients with
end-stage renal disease (ESRD).